Q-omics provides the consensus-scored AKNA profile across patient tissues and cancer cell-line models. AKNA expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, AKNA is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, AKNA RNA expression shows 19,453 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where AKNA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKNA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKNA survival associations across molecular data types. AKNA RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKNA RNA expression–survival associations across cancer types. High AKNA expression shows unfavorable associations in KIRP, but favorable associations in HNSC, LUAD, BLCA, UCEC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for AKNA RNA expression.
This table summarizes AKNA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for AKNA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKNA shows lower tumor expression in BLCA, LUSC and UCEC and higher tumor expression in KIRC, STAD and HNSC. The KIRC box plot shows higher AKNA RNA expression in tumor versus normal tissue (log2 FC = +1.379, t-test p < 0.001).
This table shows molecular features associated with AKNA in patient tissues and cancer cell lines. In patient samples, AKNA shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AKNA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
